Dapiglutide not checked
Zealand Pharma · ZP7570 · GLP-1/GLP-2 agonist
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
3 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- Copies GLP-1 or GLP-2, gut hormones. GLP-1 copies (like Ozempic) lower appetite and blood sugar; GLP-2 copies help the gut absorb food.-glutide: GLP analogues WHO name stem
- How it’s given
- “13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.”In the company’s words, NCT06000891 on ClinicalTrials.gov
- Tested for
- Safety and Tolerability, Overweight and Obesity
- Main trialPhase 1
- “The trial is a Phase 1, single-centre, randomised and double-blind within cohorts, placebo-controlled, sequential multiple ascending dose trial including three cohorts in Part 1 in a semi-parallel design and one cohort in Part 2 in overweight and obese but otherwise healthy subjects, randomised to ZP7570 or placebo within each cohort where the observational period is 18 weeks for Part 1 and 28 weeks for Part 2. All subjects will be dosed for 13 weeks in Part 1 and for 28 weeks in Part 2 with ascending weekly doses of ZP7570 at dose levels with corresponding volume of placebo.”In the company’s words, NCT06000891 on ClinicalTrials.gov
- Other names
- ZP7570 · GLP-1/GLP-2 agonist
Other drugs for Safety and Tolerability
- CagriSemaNovo Nordisk · Filed (US)
- HRS-7535Hengrui · Kailera · Filed (China)
- RibupatideHengrui · Kailera · Filed (China)
- RetatrutideEli Lilly · Phase 3
- IN-B00009HK inno.N · Phase 3
- UBT251United Laboratories · Novo Nordisk · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Terminated | 11 Feb 2025 | A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 | |
| Phase 1Completed | 12 Apr 2025 | A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide | |
| Phase 2Ended | not given | Dapiglutide for the treatment of obesity (DREAM): a randomised, double-blind, placebo-controlled, investigator-initiated trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026